The report discusses various aspects of the Protein Therapeutic Market, such as market size, area of applications and key geographical markets along with the drivers and restraints affecting the growth of each segment.
The Protein Therapeutic Market was valued in excess of US$ 57 Billion in 2006 and according to projections, it would grow at a CAGR 12.83% till 2010. The market is presently dominated by Monoclonal Antibodies and with double-digit growth projected for future, the segment is expected to bolster its dominant position. Insulin, Interferon Beta, G-CSF and coagulation factors are also exhibiting double-digit growth rates.
One of the biggest opportunity areas in the Protein Therapeutics Market will be in the field of Biogenerics, which is expected to create a multi-billion dollar market in future.
Key Findings
· US is the largest market for therapeutic proteins in the world followed by Europe and Japan.
· Insurance reimbursement is a major factor that decides the success of protein therapeutics.
· Growth in protein therapeutic market will create new opportunities for the drug discovery Contract Research Organizations (CROs).
· High expenditure on R&D and high rate of failure in phase-3 clinical trials remains a major challenge for the global protein therapeutics market.
· Until recently, protein therapeutics faced little generic threat; however, this is likely to change in future with regulatory pathways for the approval of generics already present in Europe and Asia and to be introduced in US by 2009.
Key Issues and Facts Analyzed
§ Evaluation of past, current and future market trends.
§ Discussion about the major protein therapeutics and their markets.
§ Analysis of key geographical markets.
§ Analysis of various challenges and opportunities for the industry.
§ Future prospects of the various protein therapeutics segments.
§ Profile discussion of key players in this sector.
Key Players Analyzed
This section provides the overview, key facts, and financial information of prominent players in the global protein therapeutics market, such as Amgen, Genentech, Roche Group, Merck Serono S.A, Johnson & Johnson, Novo Nordisk A/S etc.
Research Methodology Used
Information Sources
Information has been sourced from credible sources including books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
For the purpose of this report, the following segments have been included in the Protein Therapeutics Market:
Monoclonal antibodies, EPO, Interferon’s, Blood Clotting Factors, HGH, FSH, G-CSF and Insulin
The following currency conversion has been followed in the report:
1 US$ = Euros 0.73, JPY 121
Table of Contents
1. Analyst View
2. Global Therapeutic Proteins Market
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Therapeutic Proteins Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.1.4 Future Outlook (2007-2010)
3. Industry Performance
3.1 Monoclonal Antibodies (mAb)
3.1.1 Market Size
3.1.2 By Application
3.1.2.1 Oncology Treatment
3.1.2.2 Immunologic & Inflammatory Diseases Treatment
3.1.2.3 Cardiovascular & Infectious Diseases Treatment
3.1.3 Key Geographical Markets
3.1.3.1 US
3.1.3.2 Europe
3.1.3.3 Japan
3.1.4 Key Players & Drugs
3.1.5 Industry Analysis
3.1.5.1 Drivers
3.1.5.2 Restraints
3.1.6 Future Outlook (2007-2011)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.1.1 First Generation Erythropoietin
3.2.1.2 Second Generation Erythropoietin
3.2.2 By Application
3.2.2.1 Renal Anemia Treatment
3.2.2.2 Cancer Anemia Treatment
3.2.3 Key Geographical Markets
3.2.3.1 US
3.2.3.2 Europe
3.2.3.3 Japan
3.2.4 Key Players & Drugs
3.2.4.1 Erythropoietin Alpha
3.2.4.2 Erythropoietin Beta
3.2.4.3 Darbepoetin Alpha
3.2.5 Industry Analysis
3.2.5.1 Drivers
3.2.5.2 Restraints
3.2.6 Future Outlook (2007-2010)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.2.1 Diabetes Treatment
3.3.3 Key Geographical Markets
3.3.3.1 India
3.3.3.2 China
3.3.3.3 US
3.3.3.4 Russia
3.3.3.5 Japan
3.3.3.6 Germany
3.3.3.7 Brazil
3.3.4 Key Players & Drugs
3.3.5 Industry Analysis
3.3.5.1 Drivers
3.3.5.2 Restraints
3.3.6 Future Outlook (2007-2010)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.1.1 Interferon Alpha
3.4.1.1.1 By Application
3.4.1.1.1.1 Hepatitis B Treatment
3.4.1.1.1.2 Hepatitis C Treatment
3.4.1.2 Interferon Beta
3.4.1.2.1 By Application
3.4.1.2.1.1 Multiple Sclerosis Treatment
3.4.2 Key Geographical Markets
3.4.2.1 US
3.4.2.2 Europe
3.4.2.2.1 Germany
3.4.2.3 Japan
3.4.3 Key Players & Drugs
3.4.3.1 Interferon Alpha
3.4.3.2 Interferon Beta
3.4.4 Industry Analysis
3.4.4.1 Drivers
3.4.4.2 Restraints
3.4.5 Future Outlook (2007-2011)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.2.1 Pediatric Growth Hormone Deficiency Treatment
3.5.2.2 Adult Growth Hormone Deficiency Treatment
3.5.3 Key Geographical Markets
3.5.3.1 US
3.5.3.2 Europe & Japan
3.5.4 Key Players & Drugs
3.5.5 Industry Analysis
3.5.5.1 Drivers
3.5.5.2 Restraints
3.5.6 Future Outlook (2007-2010)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.1.1 Recombinant Factor VIII
3.6.1.2 Recombinant Factor VIIa
3.6.1.3 Recombinant Factor IX
3.6.2 Key Players & Drugs
3.6.3 Industry Analysis
3.6.3.1 Drivers
3.6.3.2 Restraints
3.6.4 Future Outlook (2007-2010)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players & Drugs
3.7.3 Industry Analysis
3.7.3.1 Drivers
3.7.3.2 Restraints
3.7.4 Future Outlook (2007-2010)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players & Drugs
3.8.3 Industry Analysis
3.8.3.1 Drivers
3.8.3.2 Restraints
3.8.4 Future Outlook (2007-2010)
4. Industry Analysis
4.1 Drivers
4.1.1 Higher Efficacy than Traditional Drugs
4.1.2 High Rate of Approval
4.1.3 Ageing Population
4.1.4 Healthcare Insurance
4.2 Opportunities
4.2.1 Biogenerics
4.2.2 Contract Research
4.2.3 Drug Delivery Devices
4.2.4 Healthcare Insurance
4.2.5 Drug Packaging
4.3 Challenges
4.3.1 Immunogenicity
4.3.2 High R&D Cost
4.3.3 High Price
4.3.4 High Failure Rates in Phase-3 Clinical Trials
4.3.5 Insurance Reimbursements
4.3.6 Lack of Predictability in the Operating Environment
5. Key Players
5.1 Johnson & Johnson
5.2 Biogen Idec Inc.
5.3 Eli Lilly & Company
5.4 Novo Nordisk A/S
5.5 Sanofi-Aventis
5.6 Roche Group
5.7 Amgen Inc.
5.8 Genentech, Inc.
5.9 Merck Serono S.A
5.10 Genzyme Corporation
List of Table
Table 3-1: Global - Key Players & Drugs in Erythropoietin Alpha Market by Sale (in Million US$), 2006
Table 3-2: Global - Key Players & Drugs in Erythropoietin Beta Market by Sale (in Million CHF), 2006
Table 3-3: Global - Key Players & Drugs in Darbepoetin Alpha Market by Sale (in Million US$), 2006
Table 3-4: India - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
Table 3-5: India - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 3-6: China - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
Table 3-7: China - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 3-8: US - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 3-9: US - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 3-10: Russia - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 3-11: Russia - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 3-12: Japan - Diabetic Patients in Age Group 20-79 (in '000), 2003
For more information kindly visit: http://www.bharatbook.com/
